Daklinza

Hepatitis C, Chronic, HIV Positive, Hepatitis C + 2 more

Treatment

4 FDA approvals

0 Active Studies for Daklinza

What is Daklinza

Daclatasvir

The Generic name of this drug

Treatment Summary

Daclatasvir is an oral medication used to treat chronic Hepatitis C Virus (HCV) infection. It is a direct-acting antiviral agent that prevents the virus from replicating and is usually used in combination with other drugs. It is FDA-approved to treat HCV genotypes 1 and 3 infections in both adults and children, with or without cirrhosis. Common side effects of treatment include fatigue, headaches, and nausea. Studies have shown that daclatasvir combined with other medications can achieve a sustained viral response (SVR12) in over 90% of patients with HCV genotype 1 or

Daklinza

is the brand name

image of different drug pills on a surface

Daklinza Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Daklinza

Daclatasvir

2015

3

Approved as Treatment by the FDA

Daclatasvir, otherwise called Daklinza, is approved by the FDA for 4 uses like Chronic Hepatitis C - Genotype 3 and Chronic Hepatitis C Genotype 1 .

Chronic Hepatitis C - Genotype 3

Used to treat Chronic Hepatitis C - Genotype 3 in combination with Ribavirin

Chronic Hepatitis C Genotype 1

Used to treat Chronic Hepatitis C Genotype 1 in combination with Ribavirin

Hepatitis C

Used to treat Chronic Hepatitis C - Genotype 3 in combination with Ribavirin

Hepatitis C

Used to treat Chronic Hepatitis C Genotype 1 in combination with Ribavirin

Effectiveness

How Daklinza Affects Patients

Daclatasvir is a drug that stops the hepatitis C virus from replicating in the body. It works by targeting a specific protein (NS5A) that is needed to make copies of the virus and prevents it from working properly. It is safe to take, even at doses three times higher than the recommended amount, and does not have any effect on the electrical activity in the heart.

How Daklinza works in the body

NS5A is a protein found in the cells of patients with Hepatitis C. It helps the virus to reproduce by binding to its genetic material and helping to create new copies of the virus. Daclatasvir stops this process by disrupting the proteins that help with the reproduction of the virus. It also prevents it from forming new copies of itself and spreading to other cells.

When to interrupt dosage

The suggested dosage of Daklinza is contingent upon the diagnosed condition, for instance Hepatitis C, Hepatitis C and HIV Positive. The amount of dosage can be found in the table below, relative to the mode of administration (e.g. Tablet or Oral).

Condition

Dosage

Administration

Hepatitis C

, 60.0 mg, 30.0 mg, 90.0 mg

, Oral, Tablet, Tablet - Oral

Chronic Hepatitis C

, 60.0 mg, 30.0 mg, 90.0 mg

, Oral, Tablet, Tablet - Oral

Hepatitis C, Chronic

, 60.0 mg, 30.0 mg, 90.0 mg

, Oral, Tablet, Tablet - Oral

Hepatitis C

, 60.0 mg, 30.0 mg, 90.0 mg

, Oral, Tablet, Tablet - Oral

HIV Positive

, 60.0 mg, 30.0 mg, 90.0 mg

, Oral, Tablet, Tablet - Oral

Warnings

Daklinza Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Daclatasvir may interact with Pulse Frequency

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

suspected pregnancy

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Daklinza.

Common Daklinza Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The serum concentration of Abemaciclib can be increased when it is combined with Daclatasvir.

Astemizole

Major

The metabolism of Astemizole can be decreased when combined with Daclatasvir.

Axitinib

Major

The serum concentration of Axitinib can be increased when it is combined with Daclatasvir.

Bendamustine

Major

The serum concentration of Bendamustine can be increased when it is combined with Daclatasvir.

Binimetinib

Major

The serum concentration of Binimetinib can be increased when it is combined with Daclatasvir.

Daklinza Toxicity & Overdose Risk

Common side effects from taking daclatasvir and sofosbuvir include headache, tiredness, nausea, and diarrhea. If ribavirin is added to the treatment, there may be additional side effects such as rash, difficulty sleeping, anemia, dizziness, and drowsiness. Taking all three drugs together (daclatasvir, sofosbuvir, and amiodarone) can cause a serious decrease in heart rate and is not advised unless there is no other choice.

image of a doctor in a lab doing drug, clinical research

Daklinza Novel Uses: Which Conditions Have a Clinical Trial Featuring Daklinza?

An active clinical trial is currently evaluating the potential of Daklinza to provide relief from Hepatitis C, Chronic hepatitis C genotype 2 and Hepatitis C.

Condition

Clinical Trials

Trial Phases

Hepatitis C, Chronic

0 Actively Recruiting

Hepatitis C

0 Actively Recruiting

Chronic Hepatitis C

0 Actively Recruiting

HIV Positive

0 Actively Recruiting

Hepatitis C

0 Actively Recruiting

Daklinza Reviews: What are patients saying about Daklinza?

5

Patient Review

5/31/2016

Daklinza for Chronic Infection of Genotype 3 Hepatitis C Virus

I've been taking daklinza and solvadi for hep c geno 3, and I haven't had any side effects to speak of. I make sure to drink plenty of water everyday because dehydration seems to be the only problem. I'll take my last pill today, and so far there's no virus detected. Stay positive!!!

4.7

Patient Review

12/31/2015

Daklinza for Chronic Infection of Genotype 3 Hepatitis C Virus

I'm nearing the end of a 12-week treatment, and things are looking great so far. My last two lab tests showed no viral load and normal liver enzymes. I take Daklinza with Sovaldi. The worst side effect for me has been stomach upset, but my doctor says the emotional part is due to anxiety and I am taking Valium to help with that. I really believe and pray this is my CURE. It took 5 long years before a treatment came along that my hepatologist felt I could handle.

4

Patient Review

10/25/2015

Daklinza for Chronic Infection of Genotype 3 Hepatitis C Virus

I've been taking daklinza and sovaldi for a little over a month now, and I feel great! There's the occasional nausea, but mostly just joint pain. My doctor is excited about my progress so far. I'm waiting on my first round of bloodwork results, but wanted to share my early feelings about this medication.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about daklinza

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How is daclatasvir administered?

"DAKLINZA should be taken at a dose of 60 mg, once per day, orally. It can be taken with or without food."

Answered by AI

How much does Daklinza cost?

"When Daklinza (daclatasvir) was available, the price for a 12-week course was around $63,000, but patients paid a range from $72,000 to $75,000. Bristol Myers Squibb discontinued Daklinza and the generic daclatasvir in 2019 due to business reasons."

Answered by AI

Is Daklinza discontinued?

": FDA announced Bristol Myers Squibb is discontinuing Daklinza 30mg and 60mg tablets. This follows the discontinuation of Daklinza 90mg tablets announced earlier, with distribution set to end in Dec 2018."

Answered by AI

What is Daklinza used for?

"Daklinza is an antiviral medicine that is used in combination with other medications to treat chronic hepatitis c in adults. Daklinza is effective against specific genotypes of hepatitis C, and is only indicated for certain people."

Answered by AI